Skip to main content
Erschienen in: Drugs & Aging 12/2013

01.12.2013 | Original Research Article

Use of Calcium Supplements, Vitamin D Supplements and Specific Osteoporosis Drugs Among French Women Aged 75–85 Years: Patterns of Use and Associated Factors

verfasst von: Karine Castro-Lionard, Patricia Dargent-Molina, Christophe Fermanian, Régis Gonthier, Bernard Cassou

Erschienen in: Drugs & Aging | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite the availability of effective preventive and curative medications for osteoporosis, and guidelines for its diagnosis and management, few individuals are treated for osteoporosis, even among those who have already had a fracture.

Objectives

Our objective was to describe the patterns of use of medication for osteoporosis, i.e., calcium supplements, vitamin D supplements, and specific anti-osteoporotic drugs, such as bisphosphonates, in a large sample of French older women living at home, and to identify individual factors associated with use of these medications overall and in two specific clinical situations.

Methods

Cross-sectional analysis of data from 4,221 women aged 75–85 years who participated in a balance and mobility examination as part of the screening procedure for the Ossébo study, a randomized controlled trial testing the effectiveness of exercise for the prevention of fall-related injuries. Electoral rolls were used to invite women in 16 towns to participate (participation rate 10.3 %). Information collected through questionnaires included current medication use and, in particular, use of osteoporosis medications (specific osteoporosis drugs, calcium and vitamin D supplementation) in the past 6 months, and history of fracture since the age of 50, including fracture locations. Fractures were categorized in three groups: no fracture, major osteoporotic fracture (hip, humerus, wrist, pelvis, and vertebra), and other fracture.

Results

Nearly 48 % of the participants reported they did not take calcium or vitamin D supplements or any specific osteoporosis drugs. Of the 2,133 women who reported using osteoporosis medication, 85 % used vitamin D supplements (25 % as the sole medication against this disease), 59 % calcium supplements, and 42 % a specific anti-osteoporotic drug (75 % of them combining it with vitamin D supplementation). The use of any osteoporosis medication was significantly associated (p < 0.001) with a history of a major osteoporotic fracture, lower weight, dual-energy X-ray absorptiometry (DXA) bone-density measurement in the past 5 years, a cancer-screening examination in the past 5 years, and a positive attitude toward medication use in general. Living alone was associated with a lower likelihood of using a specific anti-osteoporotic drug, and a higher education level was associated with a higher likelihood of vitamin D supplementation. Of the 1,553 women who had already had a major osteoporotic fracture, one-third (34.8 %) were not taking any osteoporosis medication. In this subgroup, use of this medication was associated with the same factors as in the overall study population. In particular, neither older age nor a history of falls in the previous 12 months was associated with a higher likelihood of using osteoporosis medication. Among the 909 women who reported using a specific osteoporosis drug, vitamin D use was associated with a higher educational level and a more frequent preventive attitude.

Conclusion

In France, as in other western countries, women aged 75 years and over are not managed according to guidelines. Further studies should address the barriers encountered in improving quality of care in osteoporosis management.
Literatur
4.
5.
Zurück zum Zitat Pignolo R. Evaluation of bone fragility and fracture prevention. In: Pignolo RJ, Keenan MA, Hebala NM, editors. Fractures in the elderly: a guide to practical management. New York: Human Press; 2011. p. 309–25.CrossRef Pignolo R. Evaluation of bone fragility and fracture prevention. In: Pignolo RJ, Keenan MA, Hebala NM, editors. Fractures in the elderly: a guide to practical management. New York: Human Press; 2011. p. 309–25.CrossRef
6.
Zurück zum Zitat Vernay M, Spongo M, Salanave B, Oléko A, et al. Statut en vitamine D de la population adulte en France: l’étude nationale nutrition santé (ENNS, 2006–2007). BEH. 2012;16–17:189–194. Vernay M, Spongo M, Salanave B, Oléko A, et al. Statut en vitamine D de la population adulte en France: l’étude nationale nutrition santé (ENNS, 2006–2007). BEH. 2012;16–17:189–194.
7.
Zurück zum Zitat Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9.PubMedCrossRef Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9.PubMedCrossRef
9.
Zurück zum Zitat Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35:293–305.PubMedCrossRef Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35:293–305.PubMedCrossRef
10.
Zurück zum Zitat Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052–7.PubMedCrossRef Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052–7.PubMedCrossRef
11.
Zurück zum Zitat Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19:79–86.PubMedCrossRef Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19:79–86.PubMedCrossRef
12.
Zurück zum Zitat Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163:2165–72.PubMedCrossRef Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163:2165–72.PubMedCrossRef
13.
Zurück zum Zitat Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18:805–10.PubMedCrossRef Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18:805–10.PubMedCrossRef
14.
Zurück zum Zitat Kaufman JD, Bolander ME, Bunta AD, et al. Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am. 2003;85-A:1837–43.PubMed Kaufman JD, Bolander ME, Bunta AD, et al. Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am. 2003;85-A:1837–43.PubMed
15.
Zurück zum Zitat Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334–8.PubMedCrossRef Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334–8.PubMedCrossRef
16.
Zurück zum Zitat Johnell K, Fastbom J. Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch Osteoporos. 2009;4:17–23.PubMedCrossRef Johnell K, Fastbom J. Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch Osteoporos. 2009;4:17–23.PubMedCrossRef
17.
Zurück zum Zitat Ankri J, Beaufils B, Ledisert B, et al. Comportement vis à vis des médicaments et représentations de soi chez des personnes âgées souffrant de maladies chroniques. Soc Sci Med. 1997;44:337–45.PubMedCrossRef Ankri J, Beaufils B, Ledisert B, et al. Comportement vis à vis des médicaments et représentations de soi chez des personnes âgées souffrant de maladies chroniques. Soc Sci Med. 1997;44:337–45.PubMedCrossRef
18.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.PubMedCrossRef
19.
Zurück zum Zitat Castel H, Bonneh DY, Sherf M, et al. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int. 2001;12:559–64.PubMedCrossRef Castel H, Bonneh DY, Sherf M, et al. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int. 2001;12:559–64.PubMedCrossRef
20.
Zurück zum Zitat Verbrugge FH, Gielen E, Milisen KK, et al. Who should receive calcium and vitamin D supplementation? Age Ageing. 2012;41:576–80.PubMedCrossRef Verbrugge FH, Gielen E, Milisen KK, et al. Who should receive calcium and vitamin D supplementation? Age Ageing. 2012;41:576–80.PubMedCrossRef
21.
Zurück zum Zitat Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012;23:2479–87.PubMedCrossRef Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012;23:2479–87.PubMedCrossRef
22.
Zurück zum Zitat Briançon D, Gaudemar (de) JB, Forestier R. Management of osteoporosis in women with peripheral osteoporotic fracture after 50 years of age: a study of practices. Joint Bone Spine. 2004;71:128–30.PubMedCrossRef Briançon D, Gaudemar (de) JB, Forestier R. Management of osteoporosis in women with peripheral osteoporotic fracture after 50 years of age: a study of practices. Joint Bone Spine. 2004;71:128–30.PubMedCrossRef
23.
Zurück zum Zitat Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–78.PubMedCrossRef Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–78.PubMedCrossRef
24.
Zurück zum Zitat Leslie WD, Giangregorio LM, Yogendran M, et al. A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving. Osteoporos Int. 2012;23:1623–9.PubMedCrossRef Leslie WD, Giangregorio LM, Yogendran M, et al. A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving. Osteoporos Int. 2012;23:1623–9.PubMedCrossRef
25.
Zurück zum Zitat Greenspan SL, Wyman A, Hooven FH, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012;60:455–61.PubMedCrossRef Greenspan SL, Wyman A, Hooven FH, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012;60:455–61.PubMedCrossRef
26.
Zurück zum Zitat Devold HM, Sogaard AJ, Tverdal AT, et al. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int. 2013;24:1225–33.PubMedCrossRef Devold HM, Sogaard AJ, Tverdal AT, et al. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int. 2013;24:1225–33.PubMedCrossRef
27.
Zurück zum Zitat Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012;79:304–13.PubMedCrossRef Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012;79:304–13.PubMedCrossRef
28.
Zurück zum Zitat Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fractures: the epidos prospective study. Lancet. 1996;348:145–9.PubMedCrossRef Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fractures: the epidos prospective study. Lancet. 1996;348:145–9.PubMedCrossRef
29.
Zurück zum Zitat INSEE. Les personnes âgées. Collection références, INSEE éditeur, Paris; 2005. INSEE. Les personnes âgées. Collection références, INSEE éditeur, Paris; 2005.
30.
Zurück zum Zitat Curtis JR, Wesfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medication among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006;15:710–8.PubMedCrossRef Curtis JR, Wesfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medication among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006;15:710–8.PubMedCrossRef
31.
Zurück zum Zitat Ismail AA, O’Neill TW, Cockerill W, et al. Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS study group. Osteoporos Int. 2000;11:248–54.PubMedCrossRef Ismail AA, O’Neill TW, Cockerill W, et al. Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS study group. Osteoporos Int. 2000;11:248–54.PubMedCrossRef
32.
Zurück zum Zitat Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong osteoporosis study. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong osteoporosis study. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef
33.
Zurück zum Zitat Peeters GM, Tett SE, Dobson AJ, et al. Validity of self-reported osteoporosis in mid-age and older women. Osteoporos Int. 2013;24:917–27.PubMedCrossRef Peeters GM, Tett SE, Dobson AJ, et al. Validity of self-reported osteoporosis in mid-age and older women. Osteoporos Int. 2013;24:917–27.PubMedCrossRef
34.
Zurück zum Zitat Dargent-Molina P, Poitiers F, Bréart G, for the EPIDOS group. In elderly women weight is the best predictor of a very low bone mineral density: evidence from the EPIDOS study. Osteoporos Int. 2000;11:881–8.PubMedCrossRef Dargent-Molina P, Poitiers F, Bréart G, for the EPIDOS group. In elderly women weight is the best predictor of a very low bone mineral density: evidence from the EPIDOS study. Osteoporos Int. 2000;11:881–8.PubMedCrossRef
35.
Zurück zum Zitat Benhamou CL, Souberbielle JC, Cortet B, et al. La vitamine D chez l’adulte: recommandations du GRIO. Presse Med. 2011;40:673–82.CrossRef Benhamou CL, Souberbielle JC, Cortet B, et al. La vitamine D chez l’adulte: recommandations du GRIO. Presse Med. 2011;40:673–82.CrossRef
36.
Zurück zum Zitat Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis: for whom and for how long. N Engl J Med. 2012;366:2051–3.PubMedCrossRef Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis: for whom and for how long. N Engl J Med. 2012;366:2051–3.PubMedCrossRef
37.
Zurück zum Zitat Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s health initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.PubMedCrossRef Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s health initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.PubMedCrossRef
Metadaten
Titel
Use of Calcium Supplements, Vitamin D Supplements and Specific Osteoporosis Drugs Among French Women Aged 75–85 Years: Patterns of Use and Associated Factors
verfasst von
Karine Castro-Lionard
Patricia Dargent-Molina
Christophe Fermanian
Régis Gonthier
Bernard Cassou
Publikationsdatum
01.12.2013
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 12/2013
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-013-0121-9

Weitere Artikel der Ausgabe 12/2013

Drugs & Aging 12/2013 Zur Ausgabe

Acknowledgement to Referees

Acknowledgments

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.